Advanced Testing, Supplements, and the Idea of “Something New”

Medicine has always changed. Some changes are incremental. Others genuinely alter what physicians can see, measure, prevent, or treat. Longevity medicine happens to be going through a period in which many of those changes are arriving at the same time.

Patients can now purchase tests directly, monitor physiology from a wrist or a sensor, obtain detailed body composition measurements, investigate cardiovascular risk beyond a conventional lipid panel, and encounter sophisticated discussions of hormones, metabolism, cognition, gut health, sleep, and nutrition without ever entering a medical office. Artificial intelligence is beginning to influence how some of that information is organized and interpreted. Imaging technology continues to improve. Laboratory medicine continues to expand.

There is a great deal to be enthusiastic about in that.

There is also a recurring tendency in healthcare and wellness marketing to present access to a new measurement as though access itself represents a medical advance. Those are not always the same thing. A new test may be useful. A familiar test may still be the better test. A technology may generate remarkable amounts of information without yet having evidence that acting on all of that information improves health outcomes.

This is where clinical judgment remains relevant.

Some of This Really Is New

It would be inaccurate to dismiss the current interest in longevity medicine by saying that physicians have been doing all of this for decades and nothing has changed.

Quite a lot has changed.

The resolution of cardiovascular imaging has improved. Coronary CT angiography can provide anatomical information that was not part of routine preventive medicine for most patients a generation ago. Newer image-analysis approaches can characterize coronary plaque in increasingly sophisticated ways. Continuous glucose monitors have moved outside the traditional boundaries of diabetes management. Consumer wearables can collect heart rate, rhythm, sleep, activity, temperature, and other physiologic information on a scale that would previously have been impractical.

Genetic testing has become inexpensive enough to reach consumers directly. Body composition testing is more accessible. Neurocognitive assessment can be performed efficiently and followed over time. Large laboratory panels can be obtained more easily than ever. Patients have access to scientific information that once remained almost entirely within medical journals and professional meetings.

Some of those developments will become increasingly important in preventive medicine. Others will prove useful only in selected situations. Some will eventually turn out to generate more information than clinical benefit.

That is normal. Medicine has always had to sort promising technology from useful technology.

Established Medicine Has Not Suddenly Become Obsolete

The excitement around newer testing can create an unintended impression that conventional medicine has somehow been measuring the wrong things.

That is not our view.

A well-selected fasting glucose, A1C, CBC, metabolic panel, TSH, ferritin, lipid panel, or other conventional laboratory test can answer an important clinical question very well. Blood pressure remains one of the most consequential measurements in preventive medicine. Family history still matters. Smoking status still matters. Exercise capacity, nutrition, sleep, medication history, alcohol use, symptoms, physical examination, and the patient's history have not become less important because a more elaborate panel can now be ordered.

Advanced testing works best when it adds information rather than merely adding volume.

We explored that in more detail in Do You Need That Lab Panel? and Why One Lab Result Doesn’t Tell the Whole Story.

A Test Has to Earn Its Place

Advanced testing is a substantial part of the HormoneSynergy® model. We use it because there are clinical questions that routine screening does not always answer adequately.

Cardiovascular risk is a good example. A conventional cholesterol panel remains useful, but it may not fully describe atherosclerotic risk in every patient. ApoB, Lp(a), carotid imaging, coronary calcium scoring, coronary CT angiography, and other tools can provide additional information when the clinical situation warrants it. Body weight alone does not describe muscle mass, bone density, or visceral fat, which is why DEXA and other body composition tools can add useful information. A fasting glucose value may be reassuring while other metabolic findings suggest that a broader assessment is appropriate.

None of this means that every patient needs every test.

Before adding a measurement, it is worth understanding what question it is intended to answer. The information should have some reasonable possibility of changing a decision, refining risk, clarifying a diagnosis, influencing treatment, or altering how the patient is followed.

Direct-to-consumer testing makes this especially important. Giving people greater access to their own health information can be valuable, but access can also place complex findings in front of patients without the clinical context needed to understand them. Genetic testing is a good example. A result may identify something important, something uncertain, or something with very little practical consequence. The report itself cannot always make that distinction for the individual patient.

More information is useful when we know what to do with it.

Supplements Deserve the Same Clinical Discipline

Nutritional supplementation is another area where old ideas, new products, emerging research, and marketing frequently overlap.

There is nothing particularly modern about using nutrients therapeutically. Physicians have treated iron deficiency, vitamin B12 deficiency, vitamin D deficiency, and other nutritional problems for generations. At the same time, nutritional science continues to evolve, formulations improve, new ingredients become available, and research changes what we know about certain compounds.

HormoneSynergy® and RetzlerRx® use and sell nutritional supplements, and we are comfortable being transparent about that. We also think supplements should be evaluated with the same practical questions we bring to other interventions: why is this being used, what dose makes sense, what evidence supports the intended use, could it interact with medications or other supplements, and does it still belong in the plan six months or several years from now?

That approach does not require an artificially short supplement list. Some patients appropriately use several products for several different reasons. Others accumulate supplements over time until nobody is entirely sure why half of them are still there.

The number is less useful than the rationale.

We discuss this more fully in Are More Supplements Better?.

Hormone Therapy Has Become More Visible, Not Newly Invented

Hormone medicine provides perhaps the clearest example of an established area of care being rediscovered by a much larger audience.

Menopausal hormone therapy, testosterone replacement, thyroid treatment, and other forms of hormone care long predate the current longevity movement. What has changed is visibility. Menopause is discussed publicly in a way it was not a decade ago. Men are exposed to testosterone advertising through television, podcasts, social media, telehealth companies, and fitness culture. Patients arrive with a much greater awareness of hormones and sometimes with strong opinions about what their levels should be before they have been medically evaluated.

Greater awareness can be beneficial. Symptoms that were once minimized may now be discussed openly. Patients may seek treatment earlier. Women have greater access to serious conversations about menopause, sexual health, bone health, and the benefits and risks of hormone therapy.

Visibility can also make hormone medicine appear simpler than it is.

The Endocrine Society reiterated in 2026 that testosterone therapy in men begins with an accurate diagnosis, including appropriate symptoms and consistently low, accurately measured testosterone concentrations. Low energy, libido, or mood alone do not establish hypogonadism because those symptoms have many potential causes. That is an important reminder in a marketplace where testosterone can easily be presented as the answer before the diagnosis is clear.

We have also become more careful about the word optimization. It can describe thoughtful individualized care, but it can just as easily imply that there is a universal ideal hormone level that everyone should pursue. There usually is not.

Our current thinking is explained in Hormone Optimization vs. Hormone Management: The Language Is Less Important Than the Medicine.

Innovation and Evidence Do Not Always Move at the Same Speed

One of the challenges in longevity medicine is that technology often advances faster than outcome research.

A new measurement may be biologically interesting long before we know whether routinely measuring it improves clinical outcomes. A wearable may detect a change in physiology without telling us whether the change is medically important. A biomarker may correlate with disease risk without evidence that treating the biomarker itself reduces that risk. A genetic result may identify susceptibility without providing a clear preventive intervention.

This does not make the information useless. It changes how confidently it should be interpreted.

Physicians routinely work with different levels of evidence. Some decisions are supported by large randomized trials and professional guidelines. Others are informed by smaller studies, observational research, physiology, clinical experience, and the circumstances of an individual patient. Preventive medicine often requires decisions before every possible question has been settled.

What we try to avoid is allowing the certainty of the marketing language to exceed the certainty of the science.

The Business of Longevity Medicine Is Not the Problem

There is now a substantial commercial marketplace surrounding longevity. Clinics charge for care. Laboratories sell testing. Imaging centers perform scans. Technology companies sell devices and subscriptions. Supplement companies sell products. HormoneSynergy® participates in that marketplace as well.

There is nothing inherently inappropriate about that. Medical practices cannot exist without revenue, and many useful medical technologies reached patients because companies invested in developing, manufacturing, testing, distributing, and explaining them.

The concern begins when the commercial structure starts determining the clinical recommendation.

If a patient is encouraged to order a test primarily because the clinic profits from the test, use a supplement because the product needs to be sold, or start treatment before the diagnosis is adequately established, the financial relationship has begun to influence the medicine in a way patients deserve to understand.

Our preference is transparency. HormoneSynergy® charges for its services. RetzlerRx® sells supplements. We may work with outside laboratories, pharmacies, imaging centers, technology companies, and other partners. In several areas of our practice, patients pay outside vendors directly rather than having another markup added by the clinic.

Medicine, Not Marketing has never meant pretending there is no business side to medicine. It means the business side should not determine what we tell a patient is medically necessary.

Clinical Context Is More Than Ordering More Things

The term personalized medicine is now used so broadly that almost any large panel or customized supplement packet can be described as individualized care.

Personalization is more demanding than that.

The same laboratory value can carry different implications in two patients because their age, symptoms, medications, family history, cardiovascular risk, body composition, previous results, and treatment goals are different. A coronary calcium score can mean something different when the patient's age and overall risk are considered. A hormone result may require treatment in one clinical setting and observation in another. An intervention that makes sense at one point in a patient's life may need to be reduced or stopped later.

Personalized care therefore includes the possibility of doing more, but it also includes the possibility of doing less.

It involves returning to the patient after the initial enthusiasm of a new intervention has passed and asking whether the intervention is still appropriate.

What Has Not Changed

For all of the technology entering longevity medicine, the basic responsibilities of medical practice remain recognizable.

The clinician still has to listen carefully enough to understand the problem. A useful history still matters. Risk has to be assessed. Testing has to be selected for a reason and interpreted correctly. Treatment needs an indication. Benefits and uncertainties should be explained honestly. Medications and supplements have to be reconciled. Follow-up matters because patients change, evidence changes, and treatment effects are not always what anyone predicted at the beginning.

New technology can make that work more informative. It cannot remove the need to do it.

How HormoneSynergy® Approaches New Tools

We are interested in innovation. We use advanced laboratory testing, cardiovascular imaging, DEXA and body composition analysis, neurocognitive testing, hormone therapy, medications, nutritional interventions, supplements, and other technologies when we believe they can contribute meaningfully to care.

We also expect our approach to change. A test we use today may become less useful when better evidence emerges. A technology we currently use selectively may eventually become routine. A treatment considered promising now may prove disappointing, while something initially regarded as niche may become standard medical care.

That willingness to change is part of evidence-based medicine rather than a departure from it.

What we do not want to change is the standard applied before something earns a place in a patient's care. The relevant questions remain clinical: what problem are we trying to solve, what does this intervention add, what are its limitations and risks, and what will we do differently because we used it?

Related HormoneSynergy® Resources

• Medicine, Not Marketing
• Do You Need That Lab Panel?
• Are More Supplements Better?
• Why One Lab Result Doesn't Tell the Whole Story
• Hormone Optimization vs. Hormone Management
• HormoneSynergy® Longevity Medicine Model
• Personalized Longevity Medicine
• Preventive Cardiology and Longevity Medicine
• Metabolic Health and Longevity Medicine
• Hormone Transitions and Longevity Medicine

Frequently Asked Questions

Is advanced testing better than conventional testing?

Not inherently. Advanced testing can provide important information when it addresses a clinical question that routine testing does not answer adequately. Many conventional tests are also exceptionally well validated and useful. The appropriate test depends on the patient, the clinical question, and whether the result is likely to influence care.

Does HormoneSynergy® use advanced laboratory testing?

Yes. HormoneSynergy® uses conventional and advanced testing as part of a broader clinical evaluation. Testing may help with diagnosis, metabolic and cardiovascular risk assessment, hormone care, nutritional evaluation, treatment selection, and follow-up when the information is clinically useful.

Are nutritional supplements part of longevity medicine?

They can be. Supplements may help correct nutrient deficiencies or support specific clinical goals, but their usefulness depends on the ingredient, dose, evidence, medications, medical history, diet, and reason for use. The number of supplements someone takes does not determine whether the plan is appropriate.

Is hormone optimization a new form of medicine?

No single medical definition of hormone optimization exists. Hormone therapy and the evaluation of hormone disorders have long been part of medicine. What is newer is the visibility and marketing of hormone care within longevity and wellness. HormoneSynergy® uses the term carefully and focuses on appropriate diagnosis, individualized treatment, risk, symptoms, and follow-up rather than pursuing universal “optimal” laboratory values.

How does HormoneSynergy® decide whether to use a newer test or technology?

The decision depends on what information the tool provides, the evidence supporting its use, its limitations and risks, the patient's clinical situation, and whether the information is likely to affect diagnosis, risk assessment, treatment, or follow-up.

Does Medicine, Not Marketing mean HormoneSynergy® is opposed to commercial healthcare products or partnerships?

No. HormoneSynergy® provides paid medical services, offers nutritional supplements, and may work with outside laboratories, imaging centers, pharmacies, technology companies, and other partners. Medicine, Not Marketing means those relationships should be transparent and should not replace the clinical rationale for recommending a test, product, or treatment.